Navigation Links
TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust
Date:9/19/2013

PHILADELPHIA, Sept. 19, 2013 /PRNewswire/ -- TREVENTIS Corporation announced today that it received a $4.4 million Seeding Drug Discovery Award from the Wellcome Trust to continue development of a potentially disease-modifying drug for the treatment of Alzheimer's disease (AD). 

Recent studies demonstrate that the misfolding and subsequent aggregation of both beta-amyloid and tau are primary events in the Alzheimer's disease process.  Using a novel, proprietary drug design platform, TREVENTIS synthesized a class of organic drug-like molecules with the unique capability of binding to both beta-amyloid and tau, preventing aggregation of both proteins using a single drug. 

This financing supports the continued progression of TREVENTIS' compounds with the initial objective of delivering an AD drug candidate into first-in-man clinical testing.  The ultimate goal is to provide a drug that effectively and safely prevents the progression of AD.

"This financing signals a transformational event for TREVENTIS.  It provides the resources necessary to progress our critically important drug development and validates the scientific approach we have taken" said William McIntosh, Chairman and CEO, TREVENTIS. 

The principal investigator, board-certified neurologist and renowned medicinal chemist, Donald F. Weaver, MD, PhD, said: "I am deeply honored to receive this funding from the Wellcome Trust.  It enables us to advance important research that will profoundly and positively impact our efforts to treat people with chronic neurological dementias such as Alzheimer's."

About TREVENTIS Corporation 
TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Toronto, Ontario, and Halifax, Nova Scotia, Canada.  The company is focused on the discovery and early stage development of disease-modifying small molecule drugs for Alzheimer's and other protein misfolding diseases.  In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring of treatment effects in Alzheimer's disease.  www.TREVENTIS.com

About Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health.  It supports the brightest minds in biomedical research and the medical humanities.  The Trust's breadth of support includes public engagement, education and the application of research to improve health.  It is independent of both political and commercial interests.  www.wellcome.ac.uk  U.S. Contact:  L. William McIntoshCanada Contact:  Dr. Mark ReedChairman and CEO, TREVENTISVP, Therapeutics, TREVENTISPhone: 610-488-608Phone: 647-924-9736wmcintosh@treventis.com  

mreed@treventis.com  


'/>"/>
SOURCE TREVENTIS Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Riley Exclusive Financial Advisor to Mirth Corporation in Connection with its Corporate Sale to Quality Systems, Inc.
2. Gentris Corporation Launches Next Generation Human Transcriptome Array
3. Euclid Systems Corporation signs agreement with Wenzhou Medical University to promote the use of Orthokeratology to control myopia progression
4. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Fourth Quarter
5. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
6. The X-Change Corporation To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website
7. Unilife Corporation To Announce Financial Results For Fiscal Year 2013 Fourth Quarter And Year End On Tuesday, September 10, 2013
8. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
9. MGC Diagnostics Corporation Reports 2013 Third Quarter Operating Results
10. Immune Pharmaceuticals Completes Merger with EpiCept Corporation
11. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Pharma To Market Pty Ltd and Ador Consulting Pte Ltd announce ... of Pharma To Market Pte Ltd, based in Singapore ... their expansion into Asia with the opening ... are delighted to appoint Joelle Chia , former owner of ... based entity. Joelle brings with her an extensive business network throughout ...
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... Prophecy concerning this present generation. Yisrayl makes an astounding statement when he says ... He explains that the Bible details the current times so plainly that anyone should ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to the La Gorce Country Club in Miami Beach to host ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):